US FDA to bring long-acting opioid REMS proposal to advisory panels
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration will seek input from its external advisors on a proposed risk evaluation and mitigation strategy (REMS) for long-acting opioids next month1.